Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Blood (2016) 128 (22): 1640.

https://doi.org/10.1182/blood.V128.22.1640.1640

Published: 2016

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

Journal Articles

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

David F. Claxton, M.D., Thomas J Myers, MD, FACP, Harry P Erba, Stefan Faderl, MD, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Clay R Warnock, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4162.

https://doi.org/10.1182/blood.V114.22.4162.4162

Published: 2009

Journal Articles

Bortezomib Improves Endothelial Thromboresistance Via Induction of KLF Transcription Factors.

Toyoko Hiroi, Clayton B Deming, Haige Zhao, Baranda S Hansen, Elisabeth K Arkenbout, Thomas J Myers, William J Riordan, Michael A McDevitt, Jeffrey J Rade

Blood (2008) 112 (11): 1890.

https://doi.org/10.1182/blood.V112.11.1890.1890

Published: 2008

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Steven P. Treon, MD, PhD, Jacob D. Soumerai, Christopher J. Patterson, Zachary R. Hunter, Irene M. Ghobrial, MD, Rose Villarreal, MS,PA-C, Michael A. Willen, MD, Thomas J. Myers, MD

Blood (2006) 108 (11): 2765.

https://doi.org/10.1182/blood.V108.11.2765.2765

Published: 2006

NARROW

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

Bortezomib Improves Endothelial Thromboresistance Via Induction of KLF Transcription Factors.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

Bortezomib Improves Endothelial Thromboresistance Via Induction of KLF Transcription Factors.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only